Secondary analysis of RxPONDER in 568 women with HR-positive, ERBB2-negative breast cancer: chemoendocrine vs endocrine therapy alone was associated with worse patient-reported cognitive function over 36 months (difference -3.02 premenopausal, -2.37 postmenopausal).
Secondary analysisn = 568
Kang et al. Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial